Treovir announces that it has been awarded a $2 million Phase 2 SBIR grant from the National Cancer Institute to advance the development of G207 in pediatric patients with recurrent glioblastoma. The SBIR grant will support a portion of the Phase 2 clinical trial patient treatment costs, regulatory costs and other company expenses.